Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. JERSEY CITY, N.J ...

In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three ...

Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is set to bolster and widen ...

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

Organon (OGN) reported $1.59 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 0.4%. EPS of $0.90 for the same period compares to $0.88 a year ago.

Explore Organon stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for OGN. When it comes to dividend performers, healthcare usually takes a backseat to options ...

In the 7th International Symposium on GnRH Analogs in Cancer and Human Reproduction, Organon presented new techniques of development of fertility In the 7th International Symposium on GnRH Analogs ...

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the ...